A Medical Device Daily Staff Report
Medtronic (Minneapolis) reported the U.S. launch of the Endurant II AAA stent graft system, which recently received FDA approval for the minimally invasive treatment of abdominal aortic aneurysms through endovascular repair (EVAR), an alternative to major surgery.
The Endurant II AAA system will be showcased at the Society for Vascular Surgery's Vascular Annual Meeting, June 7–9 at National Harbor, Maryland. Clinical performance updates on Medtronic's entire portfolio of aortic stent grafts will also be presented at the meeting.
An abdominal aortic aneurysm (AAA) is a condition in which the aorta bulges or weakens, often with no apparent symptoms.
Medtronic claims the Endurant II AAA stent graft builds on the performance of its Endurant AAA stent graft, while adding three distinct features that enhance the device's ease of use and options for clinical success:
• A lower profile delivery system with an extended hydrophilic coating improves access. The 28 mm-diameter stent graft (the most commonly used size) now fits inside an 18-French OD (outer diameter) catheter (down from 20 French in the original device).
• Two new contralateral limb lengths (156 mm and 199 mm) provide more options in sizing and can reduce the number of pieces required for an EVAR case.
• Improved radiopacity of the contralateral gate on the distal end of the device aids with limb insertion, placement and deployment.